19 October 2026

strategyland.uk

Genus PLC (GNS)

Rank #63 of 280 - Healthcare - UK Equities

Home/Stocks/Healthcare

Genus PLC

GNS.L·Healthcare·Market Cap £1.5b

Rank #63 of 280

Quantitative Model · 280 Stocks Analysed

£22.80

-12.14% YTD

52W: £19.43 - £32.20

Factor Analysis Summary

Editorial assessment generated from Genus PLC's live factor scores and sector positioning.

Based on Strategyland's proprietary 7-factor analysis, Genus PLC (GNS.L) currently holds an overall rank of #63 out of 280 FTSE 100 constituents, reflecting its weighted composite score across liquidity, valuation, profitability, solvency, asset efficiency, market trading, and technical dimensions.

Key strengths include liquidity, where it demonstrates exceptional market liquidity with deep trading volumes that support efficient entry and exit; solvency (debt/equity 0.1), where it demonstrates a sound financial footing with manageable debt levels and adequate interest coverage; and market trading, where it demonstrates healthy trading activity and market interest relative to the FTSE 100 median.

Areas requiring attention include technical (RSI 68.3), where bearish technical positioning with price trading below key trend indicators, as well as profitability (ROE 45.9%, net margin 43.4%), where profitability metrics sit near the FTSE 100 median without a clear competitive edge.

Within the Healthcare sector, Genus PLC sits at composite rank #63, outperforming the Healthcare peer average (rank 88). Among 7 Healthcare names in our coverage, it ranks above 5 peers and below 1.

Ranking in the top quartile overall, Genus PLC offers a favourable balance of fundamentals, though investors should weigh its liquidity advantage against technical — its relatively weakest factor.

Strongest Factors

Liquidity — Rank 33/280 (top quartile)
Solvency — Rank 79/280 (above average)
Market Trading — Rank 96/280 (above average)

Weakest Factors

Technical — Rank 277/280 (below average)
Profitability — Rank 153/280 (middle of the pack)

Score Analysis

Genus PLC is ranked #63 out of 280 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

129/280

Average Score

Liquidity

Excellent33/280

Valuation

Fair133/280

Profitability

Fair153/280

Solvency

Good79/280

Asset Efficiency

Fair135/280

Mkt Trading

Good96/280

Technical

Weak277/280

1. Liquidity

Score: 33/280

How liquid is GNS and can it meet its short-term obligations?

3/6

liquidity criteria met

Metric

Sector Range

Value

Rank

✓

Quick Ratio

1.0 - 2.5

1.50xRank 22/280

Range: 1.0 - 2.5Rank 22/280

✓

Current Ratio

1.5 - 2.5

2.22xRank 63/280

Range: 1.5 - 2.5Rank 63/280

✗

TTM Operating Cash Flow

0.8 - 1.5

0.60xRank 90/280

Range: 0.8 - 1.5Rank 90/280

–

Liquidity Coverage Ratio

N/A

Range: N/A

✗

Intangible Asset Ratio

5 - 20

0.05xRank 80/280

Range: 5 - 20Rank 80/280

✓

Cash-to-Debt Ratio

0.4 - 1.2

0.41xRank 104/280

Range: 0.4 - 1.2Rank 104/280

Key Liquidity Metrics

Quick Ratio

1.50x

Sector: 1.0 - 2.5

Current Ratio

2.22x

Sector: 1.5 - 2.5

Overall Liquidity Rank

Rank within universe#33/280

Best (1)Worst (280)

2. Valuation

Score: 133/280

Is GNS undervalued compared to its peers and fair value metrics?

3/7

valuation criteria met

Metric

Sector Range

Value

Rank

✓

FY27e P/E

15x - 30x

19.7xRank 196/280

Range: 15x - 30xRank 196/280

✓

FY26e P/E

15x - 30x

21.5xRank 188/280

Range: 15x - 30xRank 188/280

✓

FY27e Net Div Yld (%)

1.5 - 4.5

1.62%Rank 185/280

Range: 1.5 - 4.5Rank 185/280

–

Div Payout Ratio

30 - 60

N/ARank 25/280

Range: 30 - 60Rank 25/280

–

Current EV/EBITDA

9.0x - 16.0x

N/A

Range: 9.0x - 16.0x

–

Current P/TBV

2.0x - 7.0x

N/A

Range: 2.0x - 7.0x

–

Current P/B

2.0x - 6.0x

N/A

Range: 2.0x - 6.0x

Key Valuation Metrics

TTM P/E

Price-to-Earnings

5.4x

FY26e P/E

Forward estimate

21.5x

FY27e P/E

Forward estimate

19.7x

Current P/B

Price-to-Book

N/A

Current P/TBV

Tangible Book Value

N/A

Current EV/EBITDA

Enterprise Value

N/A

FY26e EV/EBITDA

Forward estimate

12.2x

FY27e EV/EBITDA

Forward estimate

13.0x

Dividend

GNS pays a dividend yield of 1.53%.

Current Yield

1.53%

FY27e Net Div Yield

1.62%

FY26e Gross DPS

0.352

FY27e Gross DPS

0.369

Dividend Per Share Forecast

3. Profitability

Score: 153/280

How profitable is GNS relative to its peers?

0/7

profitability criteria met

Metric

Sector Range

Value

Rank

✗

TTM Profit Margin

6 - 15

43.4%Rank 77/280

Range: 6 - 15Rank 77/280

✗

T12 FCF Margin

12 - 20

0.8%Rank 80/280

Range: 12 - 20Rank 80/280

✗

FY27e RoE

12 - 25

8.9%Rank 160/280

Range: 12 - 25Rank 160/280

✗

FY26 EPS Growth

8 - 15

-4.2%Rank 189/280

Range: 8 - 15Rank 189/280

✗

FY27e EPS Growth

8 - 15

4.5%Rank 184/280

Range: 8 - 15Rank 184/280

–

NIM

N/A

Range: N/A

–

Expense Ratio

75 - 87

N/A

Range: 75 - 87

TTM Profit Margin

43.4%

Current RoCE

45.9%

FY27e RoE

8.9%

T12 FCF Margin

0.8%

EPS Growth

4. Solvency

Score: 79/280

How strong is GNS's balance sheet and financial position?

0/6

solvency criteria met

Metric

Sector Range

Value

Rank

✗

Debt/Eqt

0.2x - 0.7x

0.14xRank 78/280

Range: 0.2x - 0.7xRank 78/280

–

Interest Coverage Ratio

5x - 15x

Rank 58Rank 58/280

Range: 5x - 15xRank 58/280

✗

Net Leverage Ratio

0.5x - 1.5x

0.44xRank 50/280

Range: 0.5x - 1.5xRank 50/280

–

Altman Z-Score (Manufacturing)

<1.10 - >2.60

9.35Rank 80/280

Range: <1.10 - >2.60Rank 80/280

–

Z-Score (Non Manufacturing)

<1.10 - >2.60

Rank 80Rank 80/280

Range: <1.10 - >2.60Rank 80/280

–

CapAdeq Ratio Tier1

N/A

Range: N/A

Key Solvency Metrics

Debt/Eqt

0.14x

Net Leverage Ratio

0.44x

Interest Coverage

Rank 58

T12 FCF Margin

0.8%

Altman Z-Score

9.35

Safe Zone

01.812.995+

5. Asset Efficiency

Score: 135/280

How efficiently does GNS deploy its assets and intellectual capital?

1/5

asset efficiency criteria met

Metric

Sector Range

Value

Rank

–

Efficiency Ratio

N/A

Range: N/A

✗

TTM Asset Turnover Ratio

0.3x - 0.6x

0.69xRank 91/280

Range: 0.3x - 0.6xRank 91/280

✗

TTM CAPEX/Sales

6 - 10

2.8%Rank 137/280

Range: 6 - 10Rank 137/280

✓

Working Capital Turnover

4x - 7x

4.96xRank 82/280

Range: 4x - 7xRank 82/280

✗

R&D/Sales FY27e

12 - 25

3.0%Rank 26/280

Range: 12 - 25Rank 26/280

Overall Asset Efficiency Rank

Rank within sector peers#135/280

Best (1)Worst (280)

6. Market Trading

Score: 96/280

How liquid and actively traded is GNS?

1/2

market trading criteria met

Metric

Sector Range

Value

Rank

✗

Intraday Sentiment (%)

30 - 60

68.0%Rank 71/280

Range: 30 - 60Rank 71/280

–

10D-Avg v/s 3M-Avg Vol

N/A

126%Rank 50/280

Range: N/ARank 50/280

✓

Avg Directional Index 30D

010 - 40

20.1Rank 135/280

Range: 010 - 40Rank 135/280

–

Parabolic SAR

N/A

2102.00Rank 55/280

Range: N/ARank 55/280

–

Stock Rating Rank

N/A

Rank 100Rank 100/280

Range: N/ARank 100/280

Market Cap

£1,511,377,787

Enterprise Value

£1,575,977,670

Trading Volume

7. Technical

Score: 277/280

What do the technical indicators say about GNS?

0/5

technical criteria met

Metric

Chart

Sector Range

Value

Rank

–

CMP v/s 52-WH

£32.20£19.43

-29.2%CMP: £22.80

N/A

-29.2%Rank 247/280

£32.20£19.43

-29.2%CMP: £22.80

Range: N/ARank 247/280

–

CMP v/s 52-WL

£32.20£19.43

+17.3%CMP: £22.80

N/A

17.3%Rank 97/280

£32.20£19.43

+17.3%CMP: £22.80

Range: N/ARank 97/280

–

RSI 14D

068.3 - Bullish100

N/A

68.3Rank 50/280

068.3 - Bullish100

Range: N/ARank 50/280

–

MA50 - MA200

£22.24-2.17£24.41

N/A

BearishRank 270/280

£22.24-2.17£24.41

Range: N/ARank 270/280

–

MACD Rank

Death Cross

MACD: 18.84

N/A

18.84Rank 100/280

Death Cross

MACD: 18.84

Range: N/ARank 100/280

RSI (14 Day)

68.3

Bullish

0 (Oversold)50100 (Overbought)

Moving Averages

50 SMA£22.24

200 SMA£24.41

SignalDeath Cross (Bearish)

MACD18.84

Risk Metrics

Beta

N/A

3-Yr Std Dev

N/A

5-Yr Std Dev

N/A

Peer Comparison

How does GNS compare to other Healthcare stocks?

Overall Rank Comparison

Factor Score Comparison

Stock	Rank	Liquidity	Valuation	Profitability	Solvency	Mkt Trading	Technical
GNS	#63	33	133	153	79	96	277
AZN.L	#4	68	242	82	111	33	248
HIK.L	#73	52	127	186	144	180	107
CVSG.L	#90	60	211	200	191	200	78
CTEC.L	#115	36	182	206	147	236	211
ONT.L	#118	28	114	262	128	64	205
HLN.L	#126	71	222	169	150	240	232

Similar Stocks

Other top-ranked stocks in the Healthcare sector

Hikma Pharmaceuticals PLC

Oxford Nanopore Technologies PLC

Catch Healthcare Events Before the Market Moves

SEC filings, FDA approvals, clinical trials, and regulatory events - scored for significance across 4 global markets.

Methodology Note

The analysis presented for Genus PLC is produced using Strategyland's proprietary 7-factor quantitative model, which evaluates each stock across Liquidity, Valuation, Profitability, Solvency, Asset Efficiency, Market Trading, and Technical dimensions. Individual factor scores and the composite rank reflect relative rankings within the FTSE 100 universe — a lower rank number indicates stronger performance in that category.

Underlying financial and market data is sourced from LSEG (London Stock Exchange Group) and processed through our scoring engine. Scores are recalculated as new data becomes available and should be interpreted as a systematic screening output, not a forecast of future share price performance.

This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance and factor rankings are not indicative of future results. Please read our Risk Disclaimer before making any investment decisions.

Strategyland Research Center - strategyland.ukThis report is for informational purposes only. Not financial advice.